[Treatment in Parkinson disease].
Takáts
Annamária
A
Semmelweis Egyetem, Altalános Orvostudományi Kar, Neurológiai Klinika, Budapest. annam@neur.sote.hu
D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001577:Benzophenones / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009570:Nitriles; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy* / Q000601:surgery; D000077867:Tolcapone
D000978:Antiparkinson Agents; D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D018680:Cholinergic Antagonists; D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D009570:Nitriles; D009596:Nitrophenols; D007980:Levodopa; C071192:entacapone; D000547:Amantadine; D000077867:Tolcapone